Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Selegiline

Detailed information about Selegiline

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH).

What to watch for:

  • Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily)
  • Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended
  • wobbly/unsteady walking (1 reports)
  • Medication error NOS (1 reports)
  • Limb non-weight bearing (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily)
  • Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended
  • wobbly/unsteady walking
  • Medication error NOS
  • Limb non-weight bearing

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Medication error NOS (1 reports)
  • Limb non-weight bearing (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:01 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 2, 2026, 11:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Image coming soon
Selegiline

Selegiline

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Tablet
Identifiers:
NADA: 141080 NDC Package: 54771-8192-1 NDC Package: 54771-8193-1 NDC Package: 54771-8194-1 NDC Package: 54771-8195-1 NDC Package: 73377-012-01 NDC Package: 73377-012-02 NDC Product: 54771 NDC Product: 73377
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily). Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily). Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
30
Species represented
1
Grouped by Body System
Neurologic (5) · Unsteady walking (ataxia), Head tremor, Head tilt - neurological disorder Behavior (2) · Behavioral disorder (unspecified), Anxiety Other (25) · Medication error NOS, Limb non-weight bearing, Knuckling
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (32)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Neurologic Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Neurologic Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (0)
  • No official label or package insert links yet.
SPL (1)
  • Anipryl® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1846/Anipryl%C2%AE
FOI (2)
  • ucm117013.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/614
  • N141080_Original_5_30_1997.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/2554
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 2, 2026, 11:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Anipryl®
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: OTC
Form/route: Tablet • Oral
Applications: NADA 141-080
Documents: 2 (FOI: 2) • SPL: 1 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 11 • Cat 0 • View
Case summaries: 5 (showing 5) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily). Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Medication error NOS (1) Limb non-weight bearing (1) Knuckling (1) Intervertebral disc disease (1) Inappropriate urination (1) Inappropriate defecation (1) Hypotension (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141080 NDC Package: 54771-8192-1 NDC Package: 54771-8193-1 NDC Package: 54771-8194-1 NDC Package: 54771-8195-1 NDC Package: 73377-012-01 NDC Package: 73377-012-02 NDC Product: 54771 NDC Product: 73377
Package NDC Product NDC Form / Route Status
54771-8192-1 54771 -
54771-8193-1 54771 -
54771-8194-1 54771 -
54771-8195-1 54771 -
73377-012-01 73377 -
73377-012-02 73377 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • N141080_Original_5_30_1997.pdf • FOI summary • Official • Dec. 13, 2017
    FDA FOI summary for application 141080
  • ucm117013.pdf • FOI summary • Official • Dec. 13, 2017
    FDA FOI summary for application 141080

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 5 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Anipryl should not be administered at doses exceeding those recommended (… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Death by euthanasia, Seizure NOS, Vomiting, Elevated alanine aminotransferase (ALT), Not eating, Inappropriate urination. (Official, 2026-02-12)
  • usage: For the control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH). For the control of clinical signs associ… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Anipryl®
OTC
Selegiline Hydrochloride
Tablet • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-080 Approved Dec 13, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains either 2, 5, 10, 15, or 30 milligrams of selegiline hydrochloride.
Dogs
Indication
For the control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH).
Dosage
1.0 mg/kg once daily, preferably administered in the morning. If no improvement is observed after 2 months of therapy, dosage may be increased to a maximum of 2.0 mg/kg once daily. If no improvement is seen after 1 month at the higher dose or if at any time clinical signs progress, the dog should be re-evaluated.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily). Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.
Indication
For the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS)
Dosage
0.5–1.0 mg/kg once daily, preferably administered in the morning. Initially, dogs should be dosed to the nearest whole tablet. Adjustments should then be made based on response and tolerance to the drug.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily). Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary
    Provides for the addition of a new claim for the clinical signs associated with canine Cognitive Dysfunction Syndrome at a new dose of 0.5-1.0mg/kg.
  • Summary

    For the control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

For the control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH). For the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS)

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily). Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Neurologic
Unsteady walking (1) • Dog Head tremor (1) • Dog Head tilt - neurological disorder (1) • Dog Grand mal seizure (1) • Dog Focal seizure (1) • Dog

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Dog Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Medication error NOS (1) • Dog Limb non-weight bearing (1) • Dog Knuckling (1) • Dog Intervertebral disc disease (1) • Dog Inappropriate urination (1) • Dog
Show more (20)
Inappropriate defecation (1) • Dog Hypotension (1) • Dog Hypoglycaemia (1) • Dog Hyperextension (1) • Dog Hyperactivity (1) • Dog Hind limb paresis (1) • Dog Hair modification NOS (1) • Dog Fever (1) • Dog Elevated serum alkaline phosphatase (1) • Dog Elevated cholesterol (1) • Dog Elevated alanine aminotransferase (1) • Dog Distress (1) • Dog Death by euthanasia (1) • Dog Collapse NOS (1) • Dog Cognitive impairment (1) • Dog Cognitive disorder NOS (1) • Dog Cervical pain (1) • Dog Brain tumour (1) • Dog Abnormal tail posture (1) • Dog Abnormal movement NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Bichon Frise, Female, 18.75 year, 3.629 kilogram • Drug: MSK, Oral • Reactions: Hyperactivity, Distress, Vocalisation • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-054128
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 18.75 Year
  • Weight: 3.629 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Hyperactivity Distress Vocalisation
Outcomes: Outcome Unknown

Dog, Brittany, Male, 13 year, 17.236 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Focal seizure, Staring, Hyperextension, Behavioral disorder (unspecified), Unsteady walking (ataxia)… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-037533
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 13.00 Year
  • Weight: 17.236 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Focal seizure Staring Hyperextension Behavioral disorder (unspecified) Unsteady walking (ataxia) Seizure NOS Vocalisation Inappropriate defecation Brain tumour Urinary tract infection Cognitive impairment Inappropriate urination Intervertebral disc disease Pacing Abnormal tail posture Abnormal movement NOS Hair modification NOS Collapse NOS Hind limb paresis Death by euthanasia Fever Anxiety Hypotension Vomiting Proprioception deficit Tremors Stridor Elevated alanine aminotransferase Elevated serum alkaline phosphatase Medication error NOS Head tilt - neurological disorder Limb non-weight bearing Cervical pain Unable to walk Overdose
Outcomes: Euthanized

Dog, Terrier - Bull - Staffordshire, Female, 13 year, 24.948 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Partial lack of efficacy, Cognitive disorder NOS, Elevated serum alkaline phosphatase, Elevated alanine aminotransferase, Elevated cholesterol… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-026646
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 24.948 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Partial lack of efficacy Cognitive disorder NOS Elevated serum alkaline phosphatase Elevated alanine aminotransferase Elevated cholesterol Thrombocytosis Knuckling Musculoskeletal disorder NOS Medication error NOS
Outcomes: Ongoing

Dog, Crossbred Canine/dog, Male, 15 year, 10.886 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Grand mal seizure, Head tremor, Hypoglycaemia, Mental function decreased • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-019063
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 10.886 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Grand mal seizure Head tremor Hypoglycaemia Mental function decreased
Outcomes: Ongoing

Dog, Crossbred Canine/dog, Male, 15 year, 10.886 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Grand mal seizure, Head tremor, Hypoglycaemia, Mental function decreased • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-003361
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 10.886 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Grand mal seizure Head tremor Hypoglycaemia Mental function decreased
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.